title: Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide.
abstract: We followed total prostate and prostatic tumor volumes in patients who received combination endocrine therapy with the antiandrogen flutamide and the LHRH agonist [D-Trp6,des-Gly-NH2(10)]LHRH ethylamide. Twenty-three men with proved prostatic adenocarcinoma (Stages B1 to D2) were subjected to a transrectal ultrasound (TRUS) study before and after a three-month period of combination antihormonal therapy. A total prostatic volume reduction ranging from 17 percent to 70 percent (median 47%, p less than 0.0001) was observed. An even greater effect was observed on tumor volume which was reduced by 20 percent to 91 percent (median 81%, p less than 0.01). After treatment, the original suspicious zone became nonvisible in 4 cases. The TRUS measurements were confirmed by direct examination of the radical prostatectomy specimen in 7 cases. TRUS is thus a precise, sensitive, and valid method for evaluating the effect of combined antihormonal therapy on normal and tumoral prostatic tissues. These data indicate that combination therapy induces a rapid and marked reduction in glandular and tumoral prostatic volume which could well improve the success of radical prostatectomy and increase the changes of cure of localized prostatic cancer.
authors.affiliation: Department of Radiology, Hôtel Dieu de Quebec, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Pinault
authors.forename: B
authors.initials: B
authors.lastname: Têtu
authors.forename: J
authors.initials: J
authors.lastname: Gagnon
authors.forename: G
authors.initials: G
authors.lastname: Monfette
authors.forename: A
authors.initials: A
authors.lastname: Dupont
authors.forename: F
authors.initials: F
authors.lastname: Labrie
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000648:ultrastructure*; D000368:Aged; D000369:Aged, 80 and over; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D012007:Rectum; D014463:Ultrasonography / Q000379:methods
chemical_list: C062225:LHRH, Trp(6)-des-GlyNH2(10)-; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide